School of Medicine


Showing 21-23 of 23 Results

  • Tamar Green

    Tamar Green

    Assistant Professor of Psychiatry and Behavioral Sciences (Interdisciplinary Brain Sciences) at the Stanford University Medical Center

    Current Research and Scholarly Interests Dr. Green is a physician-scientist and a child psychiatrist who work primarily with children with neurodevelopmental disorders such as ADHD and autism as well as with children with known genetic conditions (“neurogenetic syndromes” such as Noonan syndrome and other Rasopathies, Turner syndrome, 22q11.2 deletion syndrome). She gained her training as a child psychiatrist at Tel Aviv University in Israel. She has completed a postdoctoral research fellow in neuroscience at the Center for Interdisciplinary Brain Sciences Research at the Department of Psychiatry and Behavioral Sciences at Stanford University and currently, she is an Assistant Professor at the department. Dr. Green's research focus is the Rasopathies, a collection of syndromes associated with genetic mutations affecting the Ras/MAPK pathway. Among the Rasopathies, she is specifically interested in Noonan syndrome. These studies are directed at uncovering neural correlates associated with deficits in attention, memory and social skills in this syndrome. Results for this ongoing research also have the potential to yield valuable new insights into the role of the Ras/MAPK pathway in brain development in general, and attention, memory, and social skills.

  • Michael Greicius, MD, MPH

    Michael Greicius, MD, MPH

    Associate Professor of Neurology and, by courtesy, of Psychiatry and Behavioral Sciences

    Current Research and Scholarly Interests As the Medical Director of the Stanford Center for Memory Disorders and Principal Investigator of the Stanford Extreme Phenotypes in Alzheimer's Disease (StEP AD) Cohort, Dr. Greicius' research focuses on elucidating the neurobiologic underpinnings of AD. His lab combines cutting edge brain imaging, "deep" phenotyping, and whole-genome sequencing of human subjects to identify novel pathways involved in AD pathogenesis. The goal of his work is to develop effective treatment for AD patients.

Latest information on COVID-19